9 results about "Vasodilator agents" patented technology

The application belongs to the technical field of biomaterial preparation, and particularly relates to a composite drug delivery system based on macrophage membranes and a preparation method and application thereof. The composite drug delivery system takes a lipid nanoparticle as a drug targeting delivery carrier, coats quercetin through an active phagocytosis mode, coats a macrophage membrane on the surface of the lipid nanoparticle, and constructs a quercetin lipid nanoparticle coated with a macrophage membrane (MCM@QU@LNP). The composite drug delivery system provided by the application can promote drug enrichment in RA lesions, improve local drug exposure, realize precise drug delivery in the RA part, has good biological safety, and reduces system toxicity.

The present application relates to the field of biotechnology, in particular to astaxanthin and dihydroquercetin co-loaded liposome and its application in preparation of uric acid-lowering products. According to the steps of "in vitro function screening - optimal ratio determination - co-loaded liposome construction - surface coating and stabilization treatment - uric acid-lowering application verification", the obtained system is verified through physicochemical characterization, stability test and animal experiment. The results show that the co-loaded liposome can reduce the serum uric acid level of high uric acid model mice, inhibit the activity of liver xanthine oxidase, and improve the related indexes of kidney function and histopathological damage.

The application discloses a preparation method of dihydroquercetin self-assembled nanoparticles and application of the nanoparticles in liver protection, and the preparation method of the nanoparticles is as follows: betaine and dihydroquercetin are respectively dissolved in methanol; the methanol solutions of the betaine and the dihydroquercetin are mixed in a 1:1 molar ratio, and the pH is adjusted to 7.0-7.5 by using a sodium hydroxide solution; the mixture is added into preheated PBS under stirring, sealed and kept at 55-65 DEG C for 20-40 minutes; after being cooled to room temperature, the mixture is subjected to ultra-pure water dialysis by using a dialysis bag, and the BTNPs, i.e. dihydroquercetin self-assembled nanoparticles, are obtained after freeze-drying. The nanoparticles have good ALI treatment effect, high safety, can simultaneously solve the defects of low solubility and poor bioavailability of dihydroquercetin, and the defects of betaine, such as easy occurrence of gastrointestinal adverse reactions and existence of dose-dependent safety risks; meanwhile, the nanoparticles can also regulate intestinal flora disorder caused by alcohol and prevent endotoxemia.

This invention belongs to the field of nanobiomedicine technology, specifically relating to a mitochondrial-targeting copper-based nanoparticle (Qu@Cu-SS31) and its application in the preparation of drugs for treating myocardial infarction. The nanoparticles consist of quercetin (Que) and copper ions (Cu²⁺). + The nanoparticles, consisting of a self-assembly of the mitochondrial-targeting peptide SS31, exhibit a uniform, near-spherical morphology with an average particle size of 17.2 ± 1.6 nm. These nanoparticles specifically target cardiomyocyte mitochondria, responsively releasing Cu²⁺. + Furthermore, Qu@Cu-SS31 restores cardiomyocyte copper homeostasis by downregulating the copper metabolism negative regulator COMMD1, the copper uptake protein CTR1, and the copper chaperone protein CCS. Based on this, Qu@Cu-SS31 exhibits remarkable SOD-like and CAT-like enzyme activities, efficiently scavenging various reactive oxygen species / reactive nitrogen species and significantly reducing oxidative stress. Simultaneously, it inhibits NLRP3 inflammasome activation and Caspase-1-mediated pyroptosis, regulates the Bcl-2 / Bax balance to inhibit apoptosis, and promotes vascular endothelial growth factor expression and angiogenesis.

The present application provides a kind of drug composition and its application for targeting neuroinflammation, the composition is composed of active ingredient and natural nanometer delivery carrier for encapsulating active ingredient, the active ingredient includes fisetin, pyrrole quinoline quinone, resveratrol, bauhinia A, apigenin, saffron, quercetin and hair monkey element;The natural nanometer delivery carrier is the plant source extracellular vesicle of surface modification brain targeting molecule.The composition of the present application realizes the intervention to vascular cognitive impairment by multi-component scientific compatibility, combined with two-stage brain targeting delivery design, solves the pain points of low blood-brain barrier penetration rate and poor bioavailability of natural active ingredient, has the effect of strong anti-inflammatory and significantly improving cognitive function, excellent safety, can be used for preparing the medicine for preventing or adjuvant therapy neuroinflammation related vascular cognitive impairment, has very high clinical conversion value.

This invention discloses a dihydroquercetin cocrystal, its preparation method, and its applications. The dihydroquercetin cocrystal is prepared by combining dihydroquercetin extracted from species such as Siberian larch with small molecule substances, including betaine, L-proline, benzamide, nicotinamide, or isonicotinine. The dihydroquercetin cocrystal of this invention exhibits high thermal stability and higher apparent solubility and dissolution rate compared to dihydroquercetin itself. This facilitates the full utilization of dihydroquercetin's various pharmacological effects, such as antioxidant, antitumor, anti-apoptotic, anti-inflammatory, cardiomyocyte protection, hypoglycemic, improvement of vascular endothelial cell function, antiplatelet aggregation, and influence on bone metabolism. Furthermore, the preparation method is simple, allowing for large-scale industrial production and offering significant economic benefits.

The application belongs to the field of drug delivery and particularly relates to a composite porous stent, a composite porous drug delivery system and application. The composite porous stent comprises crosslinked oxidized hyaluronic acid, methacrylated xanthan gum, gelatin and sodium alginate; the composite porous drug delivery system is constructed by loading hyaluronic acid-coated quercetin and ginsenoside Rh2 nanoparticles on the composite porous stent, and can precisely and targetedly deliver the loaded traditional Chinese medicine components to a lesion site, so as to achieve the purpose of high-efficiency, safe and targeted treatment of breast cancer.

The application discloses a kind of pharmaceutical composition, preparation and preparation method of treating fibromyalgia syndrome, it is related to chronic pain disease treatment technical field.The pharmaceutical composition includes white flesh lucid ganoderma polysaccharide, quercetin, hesperetin and naringenin.The application further discloses a kind of pharmaceutical preparation for treating fibromyalgia syndrome and preparation method thereof.The pharmaceutical composition can effectively solve the problems of poor effect, high recurrence rate and obvious side effects of existing fibromyalgia syndrome treatment drugs;The application uses natural product to be matched, side effect is small, and can significantly improve the improvement effect on the core symptom of fibromyalgia syndrome.